

MAYER | BROWN

SETON HALL | LAW

Life Sciences Law Symposium

Disclosure Issues for Life Sciences Companies

David S. Bakst

Partner, Mayer Brown
Tel. +1 212 506 2551
dbakst@mayerbrown.com

Ilya Beylin

Associate Professor of Law, Seton Hall Law
Tel: 973 642 8810
ilya.beylin@shu.edu

February 27, 2020






Disclosure Issues for Life Sciences Companies

- Overview of Public Company Disclosure Framework
- Market Perspective
 - 2019 market overview and key takeaways
 - Outlook for 2020
 - Market impact of company milestones/catalysts
 - Financings around milestones/catalysts



Disclosure Hot Topics

- FDA Communications
 - Disclosure considerations when facing Complete Response Letters (CRLs), Serious Adverse Events (SAEs), interim clinical developments (positive and negative)
- Lawsuits, investigations (SEC, DOJ, State AG's, other regulators), enforcement actions, accounting restatements/reclassifications
 - Recent enforcement highlights
- Market perspective – what does the market really care about in these situations
- Regulation FD compliance and recent developments



Americas | Asia | Europe | Middle East

mayerbrown.com

Mayer Brown is a global services provider comprising associated legal practices that are separate entities, including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England), Mayer Brown (a Hong Kong partnership) and Taull & Chequer Advogados (a Brazilian law partnership) (collectively the "Mayer Brown Practices") and non-legal service providers, which provide consultancy services (the "Mayer Brown Consultancies"). The Mayer Brown Practices and Mayer Brown Consultancies are established in various jurisdictions and may be a legal person or a partnership. Details of the individual Mayer Brown Practices and Mayer Brown Consultancies can be found in the Legal Notices section of our website. "Mayer Brown" and the Mayer Brown logo are the trademarks of Mayer Brown. © Mayer Brown. All rights reserved.